DHR | Earnings Review — Q2 2026

DHR beat on both lines in Q2 FY2026: revenue of $6,265 million beat consensus of $6,121M by +2.4% (+5.5% YoY — the fastest of the last 8 quarters), and adjusted diluted EPS of $1.94 beat consensus of $1.85 by +4.9% (+7.8% YoY) — the 12th beat in the last 12 quarters (91.7% beat rate, zero outright misses, one in-line print). Two nuances sit underneath the clean-beat headline. First, EPS beat magnitude has now compressed for three straight quarters (Q4'25 +3.2% → Q1'26 +6.2% → Q2'26 +4.9%, versus ~9-15% through 2023-2025) as consensus catches up to a larger, better-forecasted revenue base. Second, and more important: management raised FY2026 adjusted EPS guidance to $8.45-$8.60 (from $8.35-$8.55) mostly on the early-June close of Masimo (+$0.07-$0.08 of the raise) while simultaneously narrowing and cutting the FY core revenue growth range to 3%-4% (from 3%-6%) after roughly $100M+ of bioprocessing chromatography-resin shipments were pushed by a handful of large customers into 2027. Underlying bioprocessing order growth stayed mid-teens in both consumables and equipment, so management frames the shortfall as timing, not demand deterioration — but it's the single biggest swing factor the Street is watching into Q3/Q4.

Tone: more confident on execution — Masimo called "every bit the company we thought it was," Life Sciences core growth of +5.5% its best in "several years," high-growth markets (largely China) reaccelerating to +15.4% YoY — and noticeably more cautious on bioprocessing's near-term path than a quarter ago, with a previously-flagged macro risk (Middle East conflict / resin costs) dropping out of the narrative entirely.

Contradictions (5 flagged): the FY core-growth range was cut one quarter after being called "no change"; the bioprocessing FY guide moved from high-single-digit to mid-single-digit; the respiratory revenue guide moved down twice in two quarters ($1.8B → $1.6B-$1.7B → ~$1.6B); Masimo accretion language shifted from "first full year" (pre-close) to "immediately accretive" (post-close); and a post-Masimo leverage figure (guided ~2.5x, computed 3.45x TTM) remains unreconciled against Daloopa's balance-sheet data.

Catalysts into Q3 FY2026 (~2026-10-20): whether the bioprocessing push-out reverses in FY2027 as management asserts, continued Masimo integration/synergy delivery, the pending StatLab close, and the fading respiratory/China headwinds that are mechanically driving the guided path to a mid-single-digit Q4 exit rate.

| Metric | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 | Q2'26 | |---|---|---|---|---|---|---|---|---| | Revenue ($M) | 5,798 | 6,538 | 5,741 | 5,936 | 6,053 | 6,838 | 5,951 | 6,265 | | Revenue YoY % | — | — | -0.9% | +3.4% | +4.4% | +4.6% | +3.7% | +5.5% | | Core revenue growth YoY | +0.5% | +1.0% | n/a | +1.5% | +3.0% | +2.5% | +0.5% | +3.0% | | Gross margin % | 58.7% | 59.5% | 61.2% | 59.3% | 58.2% | 58.0% | 60.3% | 57.6% | | GM YoY (bps) | — | — | +100 | -40 | -50 | -150 | -90 | -170 | | Adj. EBITDA margin % | 25.1% | 28.0% | 23.5% | 21.8% | 23.6% | 26.3% | 24.5% | 23.6% | | EBITDA margin YoY (bps) | — | — | -170 | -160 | -150 | -170 | +100 | +180 | | Adj. diluted EPS $ | 1.71 | 2.14 | 1.88 | 1.80 | 1.89 | 2.23 | 2.06 | 1.94 | | Adj. EPS YoY % | — | — | -2.1% | +4.7% | +10.5% | +4.2% | +9.6% | +7.8% |

Verdict — accelerating, with one drag. Reported revenue growth has climbed for four straight quarters (-0.9% → +5.5% YoY), core/organic growth has more than doubled off its Q1 FY2026 low (+0.5% → +3.0%), and Adjusted EBITDA margin flipped from four consecutive quarters of YoY compression to two straight quarters of expansion (+100bps, then +180bps). The offsetting signal is gross margin, down YoY for a fifth straight quarter (-170bps in Q2 FY2026, its worst print of the run) — likely Masimo integration costs and mix, and worth watching as the deal layers in further.

| Quarter | Adj. EPS Actual | EPS Consensus | EPS Beat/Miss | Revenue Actual | Revenue Consensus | Rev Beat/Miss | |---|---|---|---|---|---|---| | Q3'24 | $1.71 | $1.57 | 🟢 +8.9% | $5,798M | $5,586.9M | 🟢 +3.8% | | Q4'24 | $2.14 | $2.14 | 🟡 0.0% | $6,538M | $6,445.4M | 🟢 +1.4% | | Q1'25 | $1.88 | $1.63 | 🟢 +15.3% | $5,741M | $5,571.9M | 🟢 +3.0% | | Q2'25 | $1.80 | $1.64 | 🟢 +9.8% | $5,936M | $5,837.7M | 🟢 +1.7% | | Q3'25 | $1.89 | $1.72 | 🟢 +9.9% | $6,053M | $5,998.0M | 🟢 +0.9% | | Q4'25 | $2.23 | $2.16 | 🟢 +3.2% | $6,838M | $6,810.7M | 🟢 +0.4% | | Q1'26 | $2.06 | $1.94 | 🟢 +6.2% | $5,951M | $5,981.6M | 🔴 -0.5% | | ▶ Q2'26 (THIS QTR) | $1.94 | $1.85 | 🟢 +4.9% | $6,265M | $6,121.0M | 🟢 +2.4% |

| Window | EPS beat rate | Revenue beat rate | Pattern | |---|---|---|---| | L12Q | 11 Beat / 1 In-line / 0 Miss = 91.7% | 10 Beat / 1 Miss (data-quality outlier excluded) = 90.9% | Consistent beater | | L4Q | 4 Beat / 0 Miss = 100% | 3 Beat / 1 Miss = 75% | EPS consistent; revenue mixed (one recent miss) |

Magnitude trend: narrowing, not deteriorating. EPS beat size ran roughly 9-15% through Q3 FY2025, then compressed to 3.2% (Q4'25), 6.2% (Q1'26), and 4.9% (Q2'26) — averaging ~4.8% over the trailing three quarters vs. ~10.7% in the prior eight. Revenue's lone miss in the window (Q1 FY2026, -0.5%) was fully reversed this quarter (+2.4%). Read together, this looks like consensus tightening around DHR's own guidance ranges as visibility improves (Masimo just closed, core growth reaccelerating) rather than weakening fundamentals — guidance was raised for a second straight quarter alongside the smaller beat.

FY2026 guidance — prior vs. new (issued 2026-07-21)

| Metric | Prior FY26 Guide (Q1 call, 2026-04-21) | New FY26 Guide (Q2 call, 2026-07-21) | Change | |---|---|---|---| | Core revenue growth | 3%-6% (midpoint 4.5%) | 3%-4% (midpoint 3.5%) | Narrowed; midpoint down ~100bps | | Adjusted diluted EPS | $8.35-$8.55 (midpoint $8.45) | $8.45-$8.60 (midpoint $8.525) | Raised; midpoint +$0.075 (+0.9%) | | Bioprocessing segment growth | High-single-digit | Mid-single-digit | Cut ~200-300bps on $100M+ of shipments pushed into FY2027 | | Respiratory revenue ($) | $1.6B-$1.7B | ~$1.6B or slightly below | Trimmed to low end | | Q3 FY26 core revenue growth | Not previously guided at quarter level | 2%-3% headline (~5% ex-respiratory) | New disclosure | | Q3 FY26 adj. operating margin | n/a | ~26.5% | New disclosure | | Q4 FY26 exit rate | Mid-single-digit core growth (reaffirmed) | Mid-single-digit core growth (reaffirmed) | Unchanged |

FY2026 adjusted EPS guidance bridge

Management tone — Q1 FY2026 call vs. Q2 FY2026 call

| Dimension | Q1 FY2026 call (2026-04-21) | Q2 FY2026 call (2026-07-21) | Change | |---|---|---|---| | Overall tone | "Off to a solid start," cautious on a "dynamic" macro environment | "Particularly pleased," "encouraged by the underlying momentum" | More confident, less hedged | | Macro/geopolitical risk | Explicitly flagged Middle East conflict / oil-driven resin cost risk | Not mentioned at all | Risk dropped from the narrative | | Top-line guide confidence | Reaffirmed unchanged 3%-6% FY range, "no change" | Narrowed the FY range to 3%-4% | Lower confidence in the upper-end scenario | | EPS guide confidence | Raised modestly on Q1 beat alone | Raised again, mostly on Masimo timing rather than core beat | Recurring pattern of raising off non-organic factors | | Life Sciences | Consumables "slightly down" for the year, improving through H2 | Core growth +5.5% in Q2, best in "several years"; FY outlook raised | Biggest positive tone swing between the two calls | | Bioprocessing | High-single-digit long-term outlook; equipment orders +30% YoY cited as encouraging | Long-term outlook reaffirmed, but near-term FY guide cut to mid-single-digit on shipment timing | "Trust the long-term story, discount the next two quarters" | | M&A tone | Masimo pending, framed as strategic rationale | Masimo closed early, called "every bit the company we thought it was"; StatLab newly announced | From "why we're doing this" to "proof points it's working" |

Net read: more confident on execution/earnings and more constructive on Life Sciences, but noticeably more cautious on bioprocessing's near-term trajectory — a new, customer-concentrated risk replaced a macro risk that simply disappeared from the narrative. The FY guide reflects that mix: EPS up, revenue range narrower and lower at the midpoint.

Danaher's fiscal year is calendar-year; all growth is YoY (same calendar quarter, prior year). Q3 FY2023 uses the continuing-operations-restated revenue base ($5,624M), not the as-reported $6,873M that still included ~3 months of the Veralto spin-off, so the Q3'24 comp is apples-to-apples.

| Metric | Q3'24 | Q4'24 | Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 | Q2'26 | |---|---|---|---|---|---|---|---|---| | Revenue YoY % | +3.09% | +2.08% | -0.95% | +3.36% | +4.40% | +4.59% | +3.66% | +5.54% | | Rev accel (bps QoQ) | n/a | -102 | -303 | +431 | +104 | +19 | -93 | +188 | | GAAP diluted EPS YoY %¹ | -25.83% | +2.76% | -8.97% | -36.89% | +13.39% | +12.75% | +9.85% | +59.74% |

¹ GAAP diluted EPS is the only EPS series Daloopa carries with actuals across all 8 quarters, but it is noisy — swinging on one-time items (restructuring, deal costs, discrete tax items) that management strips out of its own guided metric. The Q2'25 print ($0.77) was a one-off trough; management's own adjusted EPS that quarter was $1.80, up ~5% YoY — which is why Q2'26's "+59.74% acceleration" above is mostly an easy compare against a depressed base, not a genuine step-change in earnings power.

Adjusted (non-GAAP) diluted EPS, per management's prepared remarks (supplementary — Daloopa carries no adjusted-EPS actuals series, only guidance ranges):

| Quarter | Adj. diluted EPS | YoY (as stated by management) | |---|---|---| | Q4 FY2024 | $2.14 | +2.4% | | Q1 FY2025 | $1.88 | not disclosed on the call | | Q2 FY2025 | $1.80 | +~5% | | Q3 FY2025 | $1.89 | +~10% | | Q4 FY2025 | $2.23 | +4% | | Q1 FY2026 | $2.06 | +9.5% | | Q2 FY2026 | $1.94 | +~8% |

Inflection points:

• Q1 FY2025 (trough): revenue -0.95% YoY, the only outright revenue decline in the window — Diagnostics China procurement/reimbursement headwinds plus soft academic/government funding hit as bioprocessing was still recovering.
• Q3 FY2025 → Q4 FY2025: revenue growth crossed above 4% and held — the first sustained (two-quarter) acceleration in the window.
• Q1 FY2026: a one-quarter revenue deceleration (-93bps) management attributed to timing, not demand — set up the "acceleration versus Q1" language on the Q2 call.
• Q2 FY2026 (current quarter): revenue growth hits +5.54% YoY, the high of the 8-quarter window, with core growth ex-respiratory accelerating ~150bps versus Q1 — achieved despite a reported ~$50-60M / ~500bps bioprocessing shipment-timing headwind that masked even stronger underlying order trends (orders +mid-teens in both consumables and equipment).

Plain-English assessment: Danaher's growth trajectory has moved from trough to inflection to acceleration over this window. Q1 FY2025 marked the bottom; from there, growth has broadly re-accelerated every quarter on a 2-quarter-average basis, reaching +5.54% YoY in Q2 FY2026 — the fastest in the series — even with a real, management-quantified bioprocessing timing drag. Strip that timing noise out and the underlying trend is stronger still: core growth ex-respiratory was 4.5% in Q2 FY2026, a ~150bps acceleration versus Q1, with Q3 guided to ~5% ex-respiratory and a mid-single-digit exit rate by Q4. GAAP diluted EPS in the table above is too noisy to read as a clean trend (the Q2'25 one-off trough mechanically inflates the Q2'26 "acceleration" print), but management's own adjusted EPS has grown YoY in every disclosed quarter this year, and full-year adjusted EPS guidance has been raised twice in 2026 alone.

| # | Catalyst | Timing | Read-through / status | |---|---|---|---| | 1 | Bioprocessing consumables push-out (~$100M+ shifted into 2027) | Ongoing; not built into Q4 recapture assumptions | Order books showed mid-teens growth in both consumables and equipment — a positive signal underlying demand outpaced shipped revenue, but multiple analysts pressed on whether this is broader destocking risk; management says no, concentrated in a handful of large accounts | | 2 | Masimo acquisition — closed early (June 10, 2026, ahead of year-end 2026 plan) | Already closed; synergy targets run through year 5 | Targeting >$125M annual cost synergies and >$50M annual sales synergies by year 5; delivered high-single-digit revenue growth in H1 2026 and launched a new FDA 510(k)-cleared AI-enabled respiratory-depression detection assay | | 3 | StatLab acquisition (Leica Biosystems) — pending | Announced 2026-07-14; expected close by year-end 2026 | ~$250M FY2025 revenue, >85% recurring, expected high-single-digit long-term growth; not yet material in consensus models | | 4 | Beckman Coulter Access p-Tau217 Alzheimer's blood test | CE Mark obtained July 2026; US FDA clearance pending | Multi-year neurodegenerative-diagnostics optionality; timing of full US clearance is the open variable | | 5 | Cepheid 3rd-gen GeneXpert + menu expansion | Unveiled at ADLM 2026 (2026-07-22); ramp through 2H FY2026/FY2027 | Core non-respiratory revenue +low-double-digits in Q2, led by hospital-acquired-infection and sexual-health assays; offsets structural respiratory-testing decline | | 6 | Respiratory testing revenue headwind unwind | Worst headwind in Q3 FY2026 (~250bps); largely gone by Q4 | Single largest mechanical swing factor in reported growth this year; FY2026 respiratory revenue guided to ~$1.6B or slightly below | | 7 | China policy headwinds (VBP/reimbursement) — lapping | Lessening through Q3/Q4 FY2026 | Beckman China declines "began to moderate as pricing stabilized and volumes improved" — first sequential-stabilization language after several pressured quarters | | 8 | Academic/government (NIH) funding | FY2027 US budget process ongoing; proposed ~13% NIH cut | Under 5% of DHR revenue; management frames it as "stability, not inflection" — no snapback assumed | | 9 | Capital deployment — buybacks + M&A optionality | Ongoing (~$900M / 5M shares repurchased in Q2 alone) | Signals management view that shares are undervalued relative to the growth/FCF outlook (FCF-to-net-income conversion 124% YTD) |

Net read: the dominant near-term catalyst is whether the ~$100M+ bioprocessing push-out is genuinely customer-specific timing or an early signal of demand softness — the swing factor the Street is most focused on into Q3/Q4. Secondary catalysts (Masimo integration ahead of plan, StatLab pending close, Cepheid/Beckman product launches, fading China/respiratory headwinds) are incrementally positive and mostly already reflected in the raised $8.45-$8.60 FY2026 EPS guide.

18 question instances across 9 analysts on the Q2 FY2026 call; 14 well answered, 4 deflected/avoided.

| Analyst (Firm) | Topic | Verdict | |---|---|---| | Michael Ryskin (BofA) | Bioprocessing shortfall — why no snapback in 2H | 🟢 Well Answered | | Michael Ryskin (BofA) | Bioprocessing visibility / order backfill | 🟢 Well Answered | | Tycho Peterson (Jefferies) | Bioprocessing equipment outlook into 2027 | 🟢 Well Answered | | Tycho Peterson (Jefferies) | Life Sciences consumables — drivers of strength | 🟢 Well Answered | | Dan Leonard (RBC) | Common thread across delayed bioprocessing customers | 🔴 Deflected/Avoided | | Dan Leonard (RBC) | Diagnostics Q3 acceleration math | 🟢 Well Answered | | Scott Davis (Melius) | Masimo early read (1 month of ownership) | 🟢 Well Answered | | Scott Davis (Melius) | Academic/government recovery shape and timing | 🔴 Deflected/Avoided | | Jack Meehan (Nephron Research) | Pall Industrial — semi vs. other end markets | 🟢 Well Answered | | Jack Meehan (Nephron Research) | Life Sciences segment guide deceleration (5.5% to 3-4%) | 🔴 Deflected/Avoided | | Vijay Kumar (Evercore ISI) | FY2027 core growth framing off Q4 exit rate | 🟢 Well Answered | | Vijay Kumar (Evercore ISI) | EPS raise math — Masimo contribution vs. guide raise size | 🟢 Well Answered | | Dan Brennan (TD Cowen) | Bioprocessing guide cushion / full-year math | 🟢 Well Answered | | Dan Brennan (TD Cowen) | Customer recourse/protections on push-outs | 🔴 Deflected/Avoided | | Casey Woodring (JP Morgan) | Bioprocessing order growth — does it include pushed-out revenue | 🟢 Well Answered | | Casey Woodring (JP Morgan) | Radiometer / Leica Biosystems back-half outlook | 🟢 Well Answered | | Patrick Donnelly (Citi) | Bioprocessing — is push-out leaking into single-use consumables | 🟢 Well Answered | | Patrick Donnelly (Citi) | Life Sciences confidence — SCIEX/mass spec detail | 🟢 Well Answered |

Net read: management was direct and quantitatively rigorous on questions with clean numeric answers (order growth, revenue bridges, EPS math, segment detail). All four deflections cluster tightly around two soft spots: (1) the actual root cause and any contractual protection around the bioprocessing customer push-outs — asked three different ways (Leonard, Brennan follow-up, Donnelly-adjacent) and never given a specific "why these customers, why now" answer beyond "resin" and "not scientific"; and (2) the timing/shape of the academic and broader Life Sciences recovery, where management leaned on optimistic framing without committing to a testable timeline. Both are worth tracking into Q3/Q4 as verification points for whether the $100M+ push-out actually ships in 2027 as asserted.

No contradictions were found in segment-level end-market commentary (pharma, academic/government, China diagnostics, Cepheid menu strategy) — that narrative was consistent across all seven transcripts on file. The five items above are guidance-figure reversals and one unreconciled data point, not narrative flip-flops.

Macro commentary: DHR's book is B2B life sciences/diagnostics — no direct rates/inflation/consumer commentary. The closest analogs:

• Biotech funding: CEO Rainer Blair said improved biotech funding is now converting from pipeline to actual orders and revenue — "previously it was just in the funnel; now we're starting to see some orders there, and also on the margins, some revenue." The closest DHR gives to a capital-markets risk-appetite read for its end markets.
• Academic/government (NIH) funding: framed explicitly as a policy question, not organic demand — management's base case is stabilization, not a snapback, and downplays the segment's importance (under 5% of revenue). Read-through: any NIH/academic-research budget shift is a macro swing factor for the broader life-science-tools group, with peers carrying larger academic exposure more sensitive than DHR.
• China policy (VBP/reimbursement): headwinds that began in late 2024 are fading — Beckman China declines "began to moderate as pricing stabilized and volumes improved." Read-through: a multi-year China healthcare-policy overhang across MedTech/diagnostics names is, in management's own view, now decelerating rather than a fresh negative.
• Industrial/semiconductor capex & reshoring: Pall Industrial grew ~10%, led by microelectronics (semiconductor/memory), tied by management to a broader reshoring dynamic in biomanufacturing capacity — constructive for semicap-exposed suppliers and reshoring-linked industrial names, though the payoff window (greenfield capacity) is multi-year, not immediate.

Companies mentioned:

| Company / theme | Relationship to DHR | Read-through | |---|---|---| | Masimo | Acquired subsidiary (closed early June 2026) | Positive standalone data point for patient-monitoring/pulse-oximetry peers — confirms underlying Masimo demand was healthy pre- and post-close | | StatLab | Pending acquisition target (Leica Biosystems) | Signals continued M&A appetite/valuation support for anatomic-pathology consumables assets — positive read for other small-cap pathology/histology consumables players | | Large commercial biopharma manufacturers (unnamed, resin customers) | Bioprocessing commercial customers | Mixed/neutral for large-scale biologics manufacturers (schedule/readiness friction at a few sites); mid-teens order growth is a positive read-through for other bioprocessing suppliers these same customers buy from (e.g. Sartorius, Repligen) | | Semiconductor/memory manufacturers (unnamed, Pall customers) | Suppliers/customers via Pall filtration | Positive read-through for semicap capex and memory-fab utilization | | NIH / academic institutions | End customers (Life Sciences, under 5% of revenue) | Neutral-to-cautious for life-science-tools peers with heavier academic exposure than DHR | | China diagnostics market (unnamed local competitors) | End market (Beckman Coulter) | Modestly positive for other diagnostics players with China exposure — suggests the VBP/pricing-driven downdraft is bottoming |

Data sourced from Daloopa (company_id 347), Danaher's Q2 FY2026 earnings call transcript (2026-07-21), and FMP historical earnings-surprise data for consensus (pulled 2026-07-25).